Replies to post #297221 on Anavex Life Sciences Corp (AVXL)

[nidan7500]

PW

I'm thinking, pre-AD, that the evidence of 2-73's benefits is going to be convincing for the authorities with efficacy in AD, Rett and PDD, but possibly not in the individual numbers for each disease that Anavex and the FDA-types arrive at an agreement that allows for the commercialization of 2-73, but with a P-4 to provide the long-term support for those decisions.

With the various analyses being done via PM/AI in three different diseases, approval in Australia, Europe and/or USA might not be as far off as some project. At least, that is my prayer for me and all those who are slipping into the AD hole as well as those already in the hole.

I am agreeing with this line of thinking. I would also add that (IMO) the risk of not doing approvals is greater than doing an approval b/c of the excellent safety profile we have w/A2-73. It is clear that patients w/CNS diseases will continue to suffer unless some action is taken. The data indicates that the worst thing that would happen w/dose approvals is that patients continue as they currently live.

Excuse the expression but..."This is a no brainer", IMO.